Dr. Abbas Khani-Hanjani MD, PhD, FRCSC
Division Head & Clinical Associate Professor, Cardiac Surgery

Abbas Khani-Hanjani finished his undergraduate and PhD degree in Experimental Medicine and Immunology at the University of British Columbia. He attended medical school at the University of Calgary and trained in the Cardiac Surgery residency program at the University of Alberta. Dr. Khani-Hanjani spent a year in Edmonton doing a fellowship in heart and lung transplantation. He then pursued a two-year fellowship in Mechanical Circulatory Support and Aortic Surgery at the Cleveland Clinic Ohio, during which he trained to perform many complex surgical cases of patients with heart failure, complex aortic pathologies and re-do surgeries. Since, he has worked as a staff member in a few Canadian centres including Foothills Hospital, Royal Columbian Hospital and the London Health Sciences Centre. Throughout his journey, Dr. Khani-Hanjani has been exposed and involved in implementing many different approaches and programs for variety of patient care; he is planning to use his expertises in implementing new programs and approaches with the team at Royal University Hospital for Cardiac Surgery patients.

Dr. Khani-Hanjani has his Royal College of Canada Certification in Cardiovascular Surgery and is a Fellow of the Royal College of Physicians and Surgeons of Canada. He also holds a Fellowship certification from the Cleveland Clinic.

Dr. Khani-Hanjani’s clinical research interests are in improving patient care by studying outcome result and quality control data; in area of basic sciences he is interested in studying the genetic basis of heart disease in populations in order to identify the modifiable risk factors for new therapeutic targets and interventions.
Dr. Khani-Hanjani believes there is an excellent opportunity for him in the Cardiac Surgery Division at the Royal University Hospital in Saskatoon to pursue both his academic and clinical goals. He is very excited to be here and be part of the Division of Cardiac Surgery and a member of the “heart team”.

During his free time, Dr. Khani-Hanjani enjoys the peacefulness of being outdoors and appreciating nature from up close

Education:
2010-2012: MCS/Heart Failure and Aortic Fellowship, Cleveland Clinic, Ohio
2004-2010: Cardiac Surgery training, University of Alberta, AB
2008-2009: Heart and Lung Transplant Fellowship, University of Alberta, AB
2001-2004: Medical Doctorate (MD), University of Calgary, AB
1995-2000: Doctorate in Immunology (PhD), University of British Columbia, BC
1991-1995: Bachelor of Science, University of British Columbia, BC

• Outcomes of Solo Smart valve in Single-Centre Experiance of 270 patients. Liu, H, Khani-Hanjani, A., Yang, S., Wang, W., Sidhu, S., Mullen, J., Modry, D., Wang, S. The Journal of Cardivascular Surgery, 59(4):633-639 April 2018.
• The Varying Effects of Obesity and Morbid Obesity on Outcomes Following Cardiac Transplantation. Jeevan Nagendran, Mathew Moore, Colleen Norris, Abbas Khani-Hanjani, Michelle Graham, Darren Freed, and Jayan Nagendran. International Journal of Obesity; January 2016.
• Case Series using the RotaFlow System for Temporary Right Ventricular Assist Device Following HeartMate II Implantation. Khani-Hanjani, A., Chamogarkakis, T., Soltesz, E. and Gonzalez-Stawinski, G. American Society of Artificial Internal Organ (ASAIO) Journal 59 (4):456-460 July/August 2013.
• Use of RotaFlow(MAQUET) for Temporary Right Ventricular Support During Implantation of HeartMate II Left Ventricular Assist Device. Loor G., Khani-Hanjani, A. and Gonzalez-Stawinski, G. American Society of Artificial Internal Organ (ASAIO) Journal 58(3):275-277 May/June 2012.
• Expression of QK/QR/RRRAA or DERAA motifs at the third Hypervariable Region of HLA-DRB1 and Disease Severity in Rheumatoid Arthritis. Khani-Hanjani A., Lacaille D., Horn C., Chalmers A., Hoar D. and Keown PA. The Journal of Rheumatology; July 2001
• Identification of Four Novel Dinucleotide Repeat Polymorphisms in the IL-2 and IL-2Rβ Genes. Khani-Hanjani A., Hoar D., Horsman D.and Keown PA. Human Immunology62(4):368-370;2001
• A Dinucleotide Repeat in a Non-Coding Region of the Interferon-γ (IFNγ) Gene Determines Susceptibility and Severity in Rheumatoid Arthritis. Khani-Hanjani A., Lacaille D., Hoar D., Chalmers A., Horsman D., Balshaw R. and Keown PA. The Lancet 356:820-825; 2000
• Identification of Four Novel Dinucleotide Repeat Polymorphisms in the TNF-α and TNF-α Genes. Khani-Hanjani A., Hoar D., Horsman D. and Keown PA. Human Immunology 61(5): 511-512; 2000

PUBLISHED ABSTRACTS AND PRESENTATIONS:

• Reoperative Mitral Valve Surgery after Previous Mitral Valve Repair. Presented in the European Society for Cardiovascular and Endovascular Surgery (ESCVS). Istanbul, Turkey March 26-29, 2015.
• The short and midterm outcomes of aortic valve replacement with Freedom Solo stentlss bioprosthesis in North America- A single center experience. Presented at the Canadian 3)Cardiovascular Society; Vancouver, Oct. 2014.
• Is recipient BMI a risk factor for adverse long-term survival post-cardiac transplantation? Presented at the Canadian Cardiovascular Society; Vancouver, Oct. 2014.
• Re-operative Aortic Valve Replacement for the Medtronic Freestyle© Stentless Valve is a Safe Operation. Presented at the AATS Istanbul, Turkey, Sep. 2014.
• Case Series using the RotaFlow System for Temporary Right Ventricular Assist Device Following HeartMate II Implantation. Presented at the 17th World Congress on Heart Disease Annual Scientific Session Toronto, July 2012.
• How has the Introduction of Flow PRA Affected Outcomes in Orthotopic Heart Transplantation – a Single Centre Experience. Presented at the Canadian Society of Transplantation (CST) meetings in Vancouver, August 2010.
• The Preoperative Levels of Panel Reactive Antibody Is Associated with Poor Outcome of Lung Transplant. Presented at the International Society of Heart and Lung Transplantation (ISHLT) meetings in Chicago, April 21 2010.
• Predictors of outcome in lung transplant: Role of Coronary artery disease. Presented at the Canadian Cardiovascular Congress meetings in Edmonton, October 2009.
• Panel reactive antibody level is associated with poor outcome in lung transplantation. Presented at the Canadian Cardiovascular Congress meetings in Edmonton, October 2009.
• Superior Gradient Reduction with Full Root Freestyle® Stentless Aortic Valve. Presented at the Canadian Cardiovascular Congress meetings in Edmonton, October 2009.
• Superior gradient reduction and better midterm survival with full root Freestyle® Stentless aortic valve replacement versus subcoronary implantation. Presented at the Fifth Biennial Meeting of The Society for Heart Valve Disease proceedings, Berlin, Germany, June 2009.
• Superior Gradient Reduction with Full Root Freestyle® Stentless Aortic Valve Replacement versus Subcoronary Implantation. Presented at the Canadian Cardiovascular Congress, Toronto, October 2008.
• Lack of association between HLA-DRB1*03 and outcome of Gold therapy for Rheumatoid Arthritis. Presented at the American College of Rheumatology, National Scientific Meeting, Boston, USA: November 1999.
• HLA and cytokine gene polymorphisms in severe Rheumatoid Arthritis. Presented at the American College of Rheumatology, National Meeting, San Diego, USA: November 1998.
• Multi-Gene analysis of disease severity in Rheumatoid Arthritis. Presented at the Arthritis Society of BC and Yukon Division, Vancouver: September 1998.
• TNF microsatellite frequencies and disease severity in Rheumatoid Arthritis. Presented at the XII Pan American congress of Rheumatology, Montreal, June 1998.
• HLA-Class II gene frequencies and disease severity in Rheumatoid Arthritis. Presented at the XII Pan American congress of Rheumatology, Montreal, June 1998.
• HLA-DRb1 frequency, TNF2 gene polymorphism and disease severity in patients with RA: a clinical perspective. Presented at the American College of Rheumatology. National Scientific Meeting, Washington, DC; USA: November 1997.
• HLA-DQb1 and DRb1-DQb1 haplotype frequencies and disease severity in patients with RA. Presented at the 23rd Annual Meeting of American Society for Histocompatibility and Immunogenetics, Atlanta, Georgia, USA: October 1997.
• HLA-DRb1 frequency, TNF2 (-308) gene polymorphism and disease severity in patients with RA. Presented at the American College of Rheumatology, Regional Meetings: Western Region, San Diego, USA: March 1997, Plenary abstract.
• HLA-DRb1 frequency, TNF2 gene polymorphism and disease severity in patients with RA: a clinical perspective. Presented at the 13th Annual Resident Research Day, University of British Columbia, Department of Medicine, Vancouver, May 1997.
• HLA-DRb1 frequency and disease severity in patients with Rheumatoid Arthritis: a clinical perspective. Presented at the Canadian Rheumatology Association Winter Workshop & Annual Meeting, Monte Tremblant, February 1997.
• HLA-DRb1 frequency and disease severity in patients with Rheumatoid Arthritis. Presented at the Arthritis Society of BC and Yukon Division Biennial Research Day, Vancouver: September 1996.
• Prognostic significance of CD34 in Acute Myelogenous Leukemia (AML). Presented at the Pathology and Hematology student Research Day, Vancouver, February 1994.